Jason D Goldman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4227621/publications.pdf

Version: 2024-02-01

38 papers 6,516 citations

394421 19 h-index 395702 33 g-index

51 all docs

51 docs citations

51 times ranked

14341 citing authors

#	Article	IF	CITATIONS
1	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. Clinical Infectious Diseases, 2024, 78, 711-718.	5.8	6
2	Remdesivir and Mortality in Patients With Coronavirus Disease 2019. Clinical Infectious Diseases, 2022, 74, 1812-1820.	5.8	25
3	Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. American Journal of Transplantation, 2022, 22, 279-288.	4.7	63
4	Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19. Nature Biotechnology, 2022, 40, 110-120.	17.5	81
5	Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022, 185, 881-895.e20.	28.9	605
6	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine, the, 2022, 10, 327-336.	10.7	131
7	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 176-188.	3.8	7
8	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clinical Infectious Diseases, 2021, 73, e4090-e4099.	5.8	332
9	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. Clinical Infectious Diseases, 2021, 72, e844-e847.	5.8	3
10	Intra-host changes in Kaposi sarcoma-associated herpesvirus genomes in Ugandan adults with Kaposi sarcoma. PLoS Pathogens, 2021, 17, e1008594.	4.7	9
11	Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. International Journal of Antimicrobial Agents, 2021, 57, 106174.	2.5	3
12	Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. Critical Care, 2021, 25, 70.	5.8	14
13	Characteristics and Factors Associated With Coronavirus Disease 2019 Infection, Hospitalization, and Mortality Across Race and Ethnicity. Clinical Infectious Diseases, 2021, 73, 2193-2204.	5.8	41
14	Perspectives on COVID-19 and cancer immunotherapy: a review series. , 2021, 9, e002489.		4
15	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies., 2021, 9, e002630.		76
16	COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. American Journal of Transplantation, 2021, 21, 2774-2784.	4.7	37
17	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1407-1418.	10.7	501
18	Healthcare resource use among solid organ transplant recipients hospitalized with COVIDâ€19. Clinical Transplantation, 2021, 35, e14174.	1.6	3

#	Article	lF	Citations
19	Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0259902.	2.5	10
20	LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial. Open Forum Infectious Diseases, 2021, 8, S808-S809.	0.9	0
21	126. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection and Vaccination. Open Forum Infectious Diseases, 2021, 8, S77-S77.	0.9	O
22	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell, 2020, 183, 1479-1495.e20.	28.9	449
23	Racial Disproportionality in Covid Clinical Trials. New England Journal of Medicine, 2020, 383, 2486-2490.	27.0	20
24	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 2020, 383, 1827-1837.	27.0	1,152
25	Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood, 2020, 136, 759-762.	1.4	124
26	Covid-19 in Critically Ill Patients in the Seattle Region â€" Case Series. New England Journal of Medicine, 2020, 382, 2012-2022.	27.0	2,120
27	Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13507.	1.6	131
28	Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation. Hepatology Communications, 2018, 2, 1446-1450.	4.3	14
29	Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 457-464.	4.9	3
30	HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection. JAMA - Journal of the American Medical Association, 2016, 316, 2044.	7.4	1
31	Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. Infectious Agents and Cancer, 2016, 11, 7.	2.6	12
32	A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999–2008. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 481-486.	2.1	40
33	Algid malaria treated with early goal-directed therapy. American Journal of Emergency Medicine, 2013, 31, 263.e5-263.e10.	1.6	2
34	HIV, hepatitis B, and hepatitis C in Zambia. Journal of Global Infectious Diseases, 2011, 3, 269.	0.5	34
35	A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics. PLoS ONE, 2010, 5, e9680.	2.5	12
36	Cryptococcosis in the immunocompetent patient. Respiratory Care, 2010, 55, 1499-503.	1.6	21

#	Article	IF	CITATIONS
37	Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2008, 24, 1031-1035.	1.1	74
38	Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling. Frontiers in Drug Discovery, 0, 2, .	2.8	1